trustmebro.to/r/…
✓ checked
trust me, bro:
here is the receipt.
the claim

In the PURPOSE 1 trial, no HIV infections occurred among women who received twice-yearly lenacapavir.

the verdict
SUPPORTED
the evidence backs this
Recorded sources
5 sources for · 0 against

Counts group repeated records of the same source within each side. They do not measure evidence strength or source independence.

Is it true that in the PURPOSE 1 trial, no HIV infections occurred among women who received twice-yearly lenacapavir?

Yes. The PURPOSE 1 primary report states that among 2,134 participants in the lenacapavir group there were 0 incident HIV infections, and a review of the PURPOSE trials likewise reports zero infections among approximately 2,134 lenacapavir recipients. CDC's 2025 recommendation also notes no HIV infections among pregnant women who received lenacapavir in that trial.

Verdict: SUPPORTED · 5 sources for, 0 against · Last checked

The private library was unavailable for some searches in this check. Missing library results are not evidence against the claim.

Evidence for · 5
Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women.
2024
Get citation
Bekker, L., Das, M., Karim, Q. A., Ahmed, K., Batting, J., Brumskine, W., Gill, K., Harkoo, I., Jaggernath, M., Kigozi, G., Kiwanuka, N., Kotze, P., Lebina, L., Louw, C. E., Malahleha, M., Manentsa, M., Mansoor, L., Moodley, D., Naicker, V., & Naidoo, L. (2024). Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women.. doi.org. https://doi.org/10.1056/NEJMoa2407001

See more details
More for · 4
Clinical Recommendation for the Use of Injectable Lenacapavir as HIV Preexposure Prophylaxis — United States, 2025 | MMWRMinusSASstats
Get citation
Clinical Recommendation for the Use of Injectable Lenacapavir as HIV Preexposure Prophylaxis — United States, 2025 | MMWRMinusSASstats. (n.d.). cdc.gov. https://www.cdc.gov/mmwr/volumes/74/wr/mm7435a1.htm

LenacDr. Pasham Umaapavir and Long-Acting HIV Therapeutics Pharmacological Mechanisms, Clinical Evidence from the PURPOSE Trials, and Future Directions in Antiretroviral Therapy
2026
Get citation
LenacDr. Pasham Umaapavir and Long-Acting HIV Therapeutics Pharmacological Mechanisms, Clinical Evidence from the PURPOSE Trials, and Future Directions in Antiretroviral Therapy. (2026). doi.org. https://doi.org/10.52403/ijrr.20260760

Clinical Recommendation for the Use of Injectable Lenacapavir as HIV Preexposure Prophylaxis - United States, 2025.
2025
Get citation
RR, P., KW, H., A, L., J, C., KM, B., & AP, K. (2025). Clinical Recommendation for the Use of Injectable Lenacapavir as HIV Preexposure Prophylaxis - United States, 2025.. doi.org. https://doi.org/10.15585/mmwr.mm7435a1

Lenacapavir and global HIV prevention: a breakthrough at risk of leaving millions behind.
2026
Get citation
GD, M. (2026). Lenacapavir and global HIV prevention: a breakthrough at risk of leaving millions behind.. doi.org. https://doi.org/10.1097/ms9.0000000000004783

Receipt History
Anyone with this link can read the claim and its public receipt, including any personal information in that text. Open permanent receipt.
Check your own claim
Challenge the receipt
Requests are recorded for review. This does not start an automatic check or guarantee a response time.

Citation formatting by citeproc-js (Frank Bennett) and the Citation Style Language project. Source and licenses.

This receipt is an automated verdict against our published method · not an opinion about any author or publication.
Terms · Privacy · How verdicts work